Journal
NETHERLANDS HEART JOURNAL
Volume 25, Issue 4, Pages 231-242Publisher
BOHN STAFLEU VAN LOGHUM BV
DOI: 10.1007/s12471-017-0959-2
Keywords
Atherosclerosis; Hypercholesterolaemia; Low-density lipoprotein; Cardiovascular disease; Statins; Proprotein convertase subtilisin/kexin type-9
Categories
Funding
- Amgen
- Astra-Zeneca
- Lilly
- Merck-Schering-Plough
- Pfizer
- Sanofi Aventis
- The Medicine Company
- Netherlands Heart Foundation
- CardioVascular Research the Netherlands (CVON)
- Interuniversity Cardiology Institute of the Netherlands
- European Community Framework KP7 Programme
Ask authors/readers for more resources
Recent years have brought a significant amount of new results in the field of atherosclerosis. A better understanding of the role of different lipoprotein particles in the formation of atherosclerotic plaques is now possible. Recent cardiovascular clinical trials have also shed more light upon the efficacy and safety of novel compounds targeting the main pathways of atherosclerosis and its cardiovascular complications. In this review, we first provide a background consisting of the current understanding of the pathophysiology and treatment of atherosclerotic disease, followed by our future perspectives on several novel classes of drugs that target atherosclerosis. The focus of this update is on the pathophysiology and medical interventions of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and lipoprotein(a) (Lp(a)).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available